13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
55 檔
62.3%
During the Q2 2024 filing period, EcoR1 Capital, LLC (CIK: 0001587114) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.1B across 55 reported positions.
During Q2 2024, EcoR1 Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 13.62% | — | +2.20% | |
| 2 | PRTA | Prothena Corporation plc | Stock-Other | 7.31% | — | — | |
| 3 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 6.80% | — | -26.70% | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 5.77% | +7.31% | — | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 5.69% | -6.61% | EXIT | |
| 6 | ARVN | Arvinas Inc | Stock-Other | 5.48% | — | — | |
| 7 | MORFUSD | Morphic Holding Inc | Stock-Other | 5.19% | — | +108.98% | |
| 8 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 4.36% | +0.31% | — | |
| 9 | KURA | Kura Oncology Inc | Stock-Other | 3.66% | — | -10.76% | |
| 10 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.50% | — | — | |
| 11 | ZYME | Zymeworks Inc | Stock-Other | 3.50% | +4.78% | — | |
| 12 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.31% | -13.69% | EXIT | |
| 13 | XNCR | Xencor Inc | Stock-Other | 3.09% | -1.12% | EXIT | |
| 14 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 2.30% | +0.88% | — | |
| 15 | JANX | Janux Therapeutics Inc | Stock-Other | 1.88% | — | — | |
| 16 | NUVB | Nuvation Bio Inc | Stock-Other | 1.72% | — | — | |
| 17 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.58% | -10.81% | EXIT | |
| 18 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 1.48% | — | +62.55% | |
| 19 | IMNM | Immunome Inc | Stock-Other | 1.44% | — | — | |
| 20 | NGNE | Neurogene Inc | Stock-Other | 1.42% | +0.85% | — | |
| 21 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.27% | — | — | |
| 22 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.19% | — | — | |
| 23 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.95% | — | — | |
| 24 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.95% | — | — | |
| 25 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 26 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.82% | — | — | |
| 27 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.74% | -0.08% | — | |
| 28 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.74% | — | — | |
| 29 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.74% | — | — | |
| 30 | PCVX | Vaxcyte Inc | Stock-Other | 0.69% | — | — | |
| 31 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.69% | — | — | |
| 32 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.67% | — | -77.53% | |
| 33 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.65% | — | — | |
| 34 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.64% | — | — | |
| 35 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.62% | — | — | |
| 36 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.56% | — | — | |
| 37 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.55% | — | -11.45% | |
| 38 | PHVS | Pharvaris N.V. | Stock-Other | 0.52% | +0.40% | NEW | |
| 39 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.46% | — | — | |
| 40 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.43% | — | — | |
| 41 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.33% | — | — | |
| 42 | KROS | Keros Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 43 | ✓ | Stock-Other | 0.25% | — | — | ||
| 44 | REPL | Replimune Group Inc | Stock-Other | 0.23% | -0.32% | EXIT | |
| 45 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 46 | GBIOGBX | Generation Bio Co | Stock-Other | 0.18% | — | — | |
| 47 | PRME | Prime Medicine Inc | Stock-Other | 0.11% | — | — | |
| 48 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.11% | +0.85% | — | |
| 49 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.10% | — | -29.18% | |
| 50 | ✓ | Hookipa Pharma | Stock-Other | 0.10% | — | +24.42% |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 55 disclosed positions in Q2 2024.
During Q2 2024, EcoR1 Capital, LLC's top holdings by market value included APLSUSD (13.6%)、PRTA (7.3%)、SRPT (6.8%). The largest single position, APLSUSD, represented 13.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, PRTA, SRPT) accounted for 62.3% of total reported equity market value during Q2 2024.
In Q2 2024, EcoR1 Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.